Interview Intersection: Expert Interviews From May 2025

Albert Chiou, MD, MBA, of Stanford University, discussed the first-in-human trial of soquelitinib, a selective ITK inhibitor, for moderate to severe atopic dermatitis. In a phase 1 trial, soquelitinib showed dose-dependent efficacy and a favorable safety profile, with up to 63% of high-dose patients achieving EASI 75 by day 28. The drug targets TH2 and TH17 pathways while sparing TH1, potentially offering a more precise immune modulation. According to Chiou, these early results suggest soquelitinib may offer a novel, targeted oral option for AD and other immune-mediated skin diseases.